225 related articles for article (PubMed ID: 35098809)
1. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.
Jiang Y; Zhang C; Lu L; Wang X; Liu H; Jiang Y; Hong L; Chen Y; Huang H; Guo D
Technol Cancer Res Treat; 2022; 21():15330338211065252. PubMed ID: 35098809
[No Abstract] [Full Text] [Related]
2. Prognostic and Predictive Value of
Jeffreys SA; Becker TM; Khan S; Soon P; Neubauer H; de Souza P; Powter B
Front Endocrinol (Lausanne); 2022; 13():895729. PubMed ID: 35784572
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of cyclin D1 expression in the survival of cancer patients: A meta-analysis.
Moradi Binabaj M; Bahrami A; Khazaei M; Ryzhikov M; Ferns GA; Avan A; Mahdi Hassanian S
Gene; 2020 Feb; 728():144283. PubMed ID: 31838249
[TBL] [Abstract][Full Text] [Related]
4. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis.
Xu XL; Chen SZ; Chen W; Zheng WH; Xia XH; Yang HJ; Li B; Mao WM
Breast Cancer Res Treat; 2013 Jun; 139(2):329-39. PubMed ID: 23670132
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies.
Li Y; Wei J; Xu C; Zhao Z; You T
PLoS One; 2014; 9(4):e94508. PubMed ID: 24728073
[TBL] [Abstract][Full Text] [Related]
6. The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis.
Ren B; Li W; Yang Y; Wu S
World J Surg Oncol; 2014 Mar; 12():55. PubMed ID: 24602161
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis.
He Q; Wu J; Liu XL; Ma YH; Wu XT; Wang WY; An HX
J BUON; 2017; 22(5):1209-1216. PubMed ID: 29135104
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis.
Zhang L; Huang Y; Lin Y; Zhang A; Zou R; Xu H; Wang S
Hematology; 2022 Dec; 27(1):122-131. PubMed ID: 35068378
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
Soverini S; Cavo M; Cellini C; Terragna C; Zamagni E; Ruggeri D; Testoni N; Tosi P; De Vivo A; Amabile M; Grafone T; Ottaviani E; Giannini B; Cangini D; Bonifazi F; Neri A; Fabris S; Tura S; Baccarani M; Martinelli G
Blood; 2003 Sep; 102(5):1588-94. PubMed ID: 12730120
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNAs (lncRNAs) as prognostic and diagnostic biomarkers in multiple myeloma: A systematic review and meta-analysis.
Mardani M; Rashedi S; Keykhaei M; Farrokhpour H; Azadnajafabad S; Tavolinejad H; Rezaei N
Pathol Res Pract; 2022 Jan; 229():153726. PubMed ID: 34942515
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis.
Li Z; Liu J; Zhang X; Fang L; Zhang C; Zhang Z; Yan L; Tang Y; Fan Y
Pathol Oncol Res; 2020 Jul; 26(3):1401-1409. PubMed ID: 31748879
[TBL] [Abstract][Full Text] [Related]
12. Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis.
Qin J; Ke B; Liu T; Kong C; Li A; Fu H; Jin C
Cancer Med; 2023 Feb; 12(3):2199-2218. PubMed ID: 36057947
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological significance of cyclin D1 expression in oral squamous cell carcinoma: A systematic review and meta-analysis.
Ramos-García P; González-Moles MÁ; González-Ruiz L; Ruiz-Ávila I; Ayén Á; Gil-Montoya JA
Oral Oncol; 2018 Aug; 83():96-106. PubMed ID: 30098785
[TBL] [Abstract][Full Text] [Related]
15. Association of
Yan H; Jiang F; Yang J
Genet Res (Camb); 2022; 2022():5338956. PubMed ID: 36072013
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 overexpression is associated with poor clinicopathological outcome and survival in oral squamous cell carcinoma in Asian populations: insights from a meta-analysis.
Zhao Y; Yu D; Li H; Nie P; Zhu Y; Liu S; Zhu M; Fang B
PLoS One; 2014; 9(3):e93210. PubMed ID: 24675814
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis.
Ding ZY; Li R; Zhang QJ; Wang Y; Jiang Y; Meng QY; Xi QL; Wu GH
Cancer Med; 2019 Jun; 8(6):2717-2729. PubMed ID: 30950241
[TBL] [Abstract][Full Text] [Related]
18. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma.
Rasmussen T; Knudsen LM; Johnsen HE
Eur J Haematol; 2001; 67(5-6):296-301. PubMed ID: 11872077
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
